Table 2 Patient characteristics analyzed in our study (n = 61)
Age, year | |
 Median | 64 |
 Range | 39–84 |
Sex, n (%) | |
 Female | 44 (72%) |
 Male | 17 (28%) |
Smoking history, n (%) | |
 Never | 44 (72%) |
 Former/Current | 17 (28%) |
ECOG performance status, n (%) | |
 0–1 | 52 (85%) |
 2–4 | 9 (15%) |
Pretreatment EGFR status, n (%) | |
 Exon19 deletion | 37 (61%) |
 Exon21 L858R | 19 (31%) |
 Other | 5 (8%) |
EGFR TKI, n (%) | |
 Gefitinib | 49 (80%) |
 Erlotinib | 7 (12%) |
 2nd generation | 5 (8%) |